Bank of Montreal Can Has $4.64 Million Stake in Repligen Co. (NASDAQ:RGEN)

Bank of Montreal Can raised its stake in Repligen Co. (NASDAQ:RGEN) by 4.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 36,752 shares of the biotechnology company’s stock after buying an additional 1,575 shares during the quarter. Bank of Montreal Can owned 0.07% of Repligen worth $4,641,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the stock. CWM LLC lifted its stake in Repligen by 19.9% in the first quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 60 shares during the period. DekaBank Deutsche Girozentrale increased its holdings in shares of Repligen by 1.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company’s stock worth $982,000 after acquiring an additional 89 shares in the last quarter. Diversified Trust Co grew its holdings in shares of Repligen by 3.7% during the second quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company’s stock worth $372,000 after buying an additional 106 shares in the last quarter. O Shaughnessy Asset Management LLC grew its holdings in shares of Repligen by 6.9% during the first quarter. O Shaughnessy Asset Management LLC now owns 1,924 shares of the biotechnology company’s stock worth $354,000 after buying an additional 125 shares in the last quarter. Finally, V Square Quantitative Management LLC grew its holdings in shares of Repligen by 23.6% during the second quarter. V Square Quantitative Management LLC now owns 697 shares of the biotechnology company’s stock worth $88,000 after buying an additional 133 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Stephens reiterated an “overweight” rating and set a $170.00 price objective on shares of Repligen in a report on Tuesday, July 30th. Wells Fargo & Company assumed coverage on Repligen in a report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price objective for the company. Deutsche Bank Aktiengesellschaft upgraded Repligen from a “hold” rating to a “buy” rating and decreased their price objective for the stock from $180.00 to $155.00 in a report on Wednesday, June 26th. JPMorgan Chase & Co. raised their price target on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 31st. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $205.00 price target on shares of Repligen in a research note on Thursday, September 26th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Repligen has an average rating of “Moderate Buy” and a consensus target price of $190.25.

Repligen Stock Performance

RGEN opened at $145.74 on Wednesday. Repligen Co. has a 12-month low of $110.45 and a 12-month high of $211.13. The stock has a market cap of $8.16 billion, a price-to-earnings ratio of 582.98, a PEG ratio of 4.32 and a beta of 0.94. The business has a 50 day moving average of $149.18 and a 200-day moving average of $152.84. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.33. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The company had revenue of $154.07 million during the quarter, compared to analysts’ expectations of $154.11 million. During the same period last year, the firm posted $0.53 earnings per share. The business’s revenue was down 3.2% on a year-over-year basis. On average, equities research analysts expect that Repligen Co. will post 1.45 earnings per share for the current year.

Insider Buying and Selling

In related news, VP Ralf Kuriyel sold 4,465 shares of Repligen stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the completion of the sale, the vice president now directly owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Ralf Kuriyel sold 4,465 shares of Repligen stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the transaction, the vice president now directly owns 19,261 shares of the company’s stock, valued at $3,190,969.87. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.